JPWO2022204328A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022204328A5 JPWO2022204328A5 JP2023557007A JP2023557007A JPWO2022204328A5 JP WO2022204328 A5 JPWO2022204328 A5 JP WO2022204328A5 JP 2023557007 A JP2023557007 A JP 2023557007A JP 2023557007 A JP2023557007 A JP 2023557007A JP WO2022204328 A5 JPWO2022204328 A5 JP WO2022204328A5
- Authority
- JP
- Japan
- Prior art keywords
- metered dose
- dose inhaler
- pressurized
- formulation
- oral
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229940071648 metered dose inhaler Drugs 0.000 claims description 41
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 claims description 21
- 229930182837 (R)-adrenaline Natural products 0.000 claims description 20
- 229960005139 epinephrine Drugs 0.000 claims description 20
- 206010020751 Hypersensitivity Diseases 0.000 claims description 8
- 230000006461 physiological response Effects 0.000 claims description 6
- 206010044565 Tremor Diseases 0.000 claims description 5
- 208000024891 symptom Diseases 0.000 claims description 5
- 206010002198 Anaphylactic reaction Diseases 0.000 claims description 4
- 208000003455 anaphylaxis Diseases 0.000 claims description 4
- 230000036783 anaphylactic response Effects 0.000 claims description 3
- 208000026935 allergic disease Diseases 0.000 claims description 2
- 230000007815 allergy Effects 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims 21
- 239000000203 mixture Substances 0.000 claims 21
- 210000003800 pharynx Anatomy 0.000 claims 12
- 239000008186 active pharmaceutical agent Substances 0.000 claims 9
- 210000000867 larynx Anatomy 0.000 claims 8
- 210000004072 lung Anatomy 0.000 claims 8
- 238000000034 method Methods 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 7
- 239000003380 propellant Substances 0.000 claims 6
- 239000006184 cosolvent Substances 0.000 claims 4
- 230000008447 perception Effects 0.000 claims 4
- 239000012458 free base Substances 0.000 claims 2
- 208000001871 Tachycardia Diseases 0.000 claims 1
- 230000001668 ameliorated effect Effects 0.000 claims 1
- 239000003963 antioxidant agent Substances 0.000 claims 1
- 230000003078 antioxidant effect Effects 0.000 claims 1
- 239000004094 surface-active agent Substances 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 230000006794 tachycardia Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163165102P | 2021-03-23 | 2021-03-23 | |
| US63/165,102 | 2021-03-23 | ||
| PCT/US2022/021612 WO2022204328A1 (en) | 2021-03-23 | 2022-03-23 | Device for treating anaphylaxis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024515446A JP2024515446A (ja) | 2024-04-10 |
| JPWO2022204328A5 true JPWO2022204328A5 (enrdf_load_stackoverflow) | 2025-04-18 |
Family
ID=81307871
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023557007A Pending JP2024515446A (ja) | 2021-03-23 | 2022-03-23 | アナフィラキシーを処置するためのデバイス |
Country Status (18)
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025072756A1 (en) * | 2023-09-28 | 2025-04-03 | Kokua Pharma Inc. | Device, methods, and uses for treating acute allergic reactions |
| WO2025170986A1 (en) * | 2024-02-06 | 2025-08-14 | Kindeva Drug Delivery L.P. | Drug delivery device |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9324250D0 (en) * | 1993-11-25 | 1994-01-12 | Minnesota Mining & Mfg | Inhaler |
| EP1321159A1 (en) | 2001-12-21 | 2003-06-25 | CHIESI FARMACEUTICI S.p.A. | Pressurized metered dose inhaler (pMDI) actuators with laser drilled orifices |
| ES2867378T3 (es) * | 2002-06-28 | 2021-10-20 | Civitas Therapeutics Inc | Epinefrina inhalable |
| WO2004112702A2 (en) * | 2003-06-13 | 2004-12-29 | Advanced Inhalation Research, Inc. | Low dose pharmaceutical powders for inhalation |
| CN101175479A (zh) * | 2005-03-16 | 2008-05-07 | 霍尼韦尔国际公司 | 药物递送制剂、装置和方法 |
| US8367734B1 (en) | 2005-08-11 | 2013-02-05 | Amphastar Pharmaceuticals Inc. | Stable epinephrine suspension formulation with high inhalation delivery efficiency |
| GB0801876D0 (en) * | 2008-02-01 | 2008-03-12 | Vectura Group Plc | Suspension formulations |
| SG189892A1 (en) * | 2010-10-12 | 2013-06-28 | Ivax Pharmaceuticals Ireland | Nasal spray device |
| US20120204871A1 (en) * | 2011-02-10 | 2012-08-16 | Julio Cesar Vega | Stable, non-corrosive formulations for pressurized metered dose inhalers |
| IN2015DN01597A (enrdf_load_stackoverflow) * | 2012-08-29 | 2015-07-03 | Chiesi Farma Spa | |
| US10039710B2 (en) * | 2015-09-18 | 2018-08-07 | Insys Development Company, Inc. | Epinephrine spray formulations |
| US9717683B1 (en) * | 2016-06-29 | 2017-08-01 | Ep Pharma, Llc | Low-temperature inhalation administration of cannabinoid entities |
-
2022
- 2022-03-23 CA CA3212189A patent/CA3212189A1/en active Pending
- 2022-03-23 KR KR1020237032955A patent/KR20230165764A/ko active Pending
- 2022-03-23 SI SI202230117T patent/SI4188332T1/sl unknown
- 2022-03-23 IL IL305534A patent/IL305534A/en unknown
- 2022-03-23 AU AU2022245300A patent/AU2022245300A1/en active Pending
- 2022-03-23 CN CN202280024727.6A patent/CN117083054A/zh active Pending
- 2022-03-23 DK DK22716648.5T patent/DK4188332T3/da active
- 2022-03-23 FI FIEP22716648.5T patent/FI4188332T3/fi active
- 2022-03-23 WO PCT/US2022/021612 patent/WO2022204328A1/en active IP Right Grant
- 2022-03-23 EP EP22716648.5A patent/EP4188332B1/en active Active
- 2022-03-23 EP EP24223644.6A patent/EP4545122A3/en active Pending
- 2022-03-23 US US17/702,733 patent/US20220331237A1/en active Pending
- 2022-03-23 LT LTEPPCT/US2022/021612T patent/LT4188332T/lt unknown
- 2022-03-23 ES ES22716648T patent/ES3025005T3/es active Active
- 2022-03-23 JP JP2023557007A patent/JP2024515446A/ja active Pending
- 2022-03-23 PT PT227166485T patent/PT4188332T/pt unknown
- 2022-03-23 RS RS20250407A patent/RS66787B1/sr unknown
- 2022-03-23 BR BR112023019156A patent/BR112023019156A2/pt unknown
- 2022-03-23 HR HRP20250566TT patent/HRP20250566T1/hr unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7621220B2 (ja) | 疾患の処置のための鼻腔内エピネフリン製剤及び方法 | |
| CA2914089C (en) | Nicotine-containing liquid formulations and uses thereof | |
| AU2017265011B2 (en) | Methods of administering high concentrations of nitric oxide | |
| TWI278324B (en) | Dry powder for use in the preparation of medicament for the treatment of chronic obstructive pulmonary disease | |
| JP5886630B2 (ja) | 重度で抑制されていないぜんそくの治療方法、装置、および組成物 | |
| US20020033174A1 (en) | Inhalable aerosol medicament for the treatment or prevention of pain | |
| MXPA04012041A (es) | Una composicion liquida y regulada de nicotina para administracion pulmonar. | |
| Hetzel et al. | Comparison of salbutamol Rotahaler with conventional pressurized aerosol | |
| Ikeda et al. | Comparative dose-response study of three anticholinergic agents and fenoterol using a metered dose inhaler in patients with chronic obstructive pulmonary disease. | |
| EP2825179B1 (en) | Methods of administering high concentrations of nitric oxide | |
| JP2005508963A (ja) | 喘息を治療するためのサルメテロールとフルチカゾンプロピオネートを含む医薬の組み合せ | |
| Tu et al. | Localized delivery of nanomedicine and antibodies for combating COVID-19 | |
| JP2004507494A (ja) | サルメテロールとプロピオン酸フルチカゾンとの合剤の使用 | |
| TORNETTA | A comparison of droperidol, diazepam, and hydroxyzine hydrochloride as premedication | |
| US10383883B2 (en) | Treatment of congestion using steroids and adrenergics | |
| O Callaghan et al. | The history of inhaled drug therapy | |
| JPWO2022204328A5 (enrdf_load_stackoverflow) | ||
| US3050443A (en) | Headache remedy containing ammonia | |
| US10966988B2 (en) | Method for smoking cessation | |
| Almukhambetova et al. | Nebulising therapy of bronchial asthma attacks | |
| Woodhead et al. | Long-term Safety Data of Inhaled Pirfenidone (AP01) in Idiopathic Pulmonary Fibrosis (IPF) and Non-IPF Interstitial Lung Disease (ILD) Patients | |
| US20210220371A1 (en) | Method for smoking cessation | |
| HK40072978A (en) | Methods of administering high concentrations of nitric oxide | |
| Pauwels | Inhalation device, pulmonary deposition and clinical effects of inhaled therapy | |
| CN115697346A (zh) | 适应障碍的治疗 |